We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cephalon announced that German regulators have expanded the approval of the
company's sleep disorder treatment to include a condition called "chronic
shift work sleep disorder."
Australian adult stem cell company, Mesoblast has commenced preclinical trials
at Colorado State University in support of its investigational new drug submissions
to the FDA.
Emergent BioSolutions announced positive results from a Phase II clinical study
evaluating a new simplified dosing regimen for the company's next generation
single-dose oral typhoid vaccine.
Viragen announced that data from its Phase II/III clinical study evaluating
Multiferon, natural human alpha interferon, for the adjuvant treatment of malignant
melanoma will be presented at the Sixth World Congress on Melanoma, to be held
in Vancouver, Canada.
Momenta Pharmaceuticals announced that an abbreviated new drug application (ANDA) seeking marketing approval of M-Enoxaparin has been filed with the FDA.